Search
Now showing items 1-2 of 2
Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.
(
AME Publishing Company
, 2017 , Article)
CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors
Letter to the Editor/Response
(
Blackwell Publishing Inc.
, 2019 , Article)
[No abstract available]